StockTitan

@stocktitan.net

6 days ago

Quanterix Corporation Announces Date of 2026 Annual Meeting Quanterix (NASDAQ: QTRX) announced its 2026 annual meeting of shareholders will be held virtually on June 9, 2026 at 10:00 AM ET. Stockholders of record as of April 14, 2026 may vote. The company set an April 6, 2026 deadline for shareholder proposals and director nominations.Additional meeting details and proxy materials will be provided in the company's proxy statement.

#QTRX Quanterix Corporation Announces Date of 2026 Annual Meeting

www.stocktitan.net/news/QTRX/quanterix-corp...

StockTitan

@stocktitan.net

1 month ago

Quanterix Releases Financial Results for the Fourth Quarter and Full Year 2025 Quanterix (NASDAQ: QTRX) reported Q4 2025 revenue of $43.9 million (+25% YoY) and full‑year 2025 revenue of $138.9 million (+1% YoY). GAAP gross margin declined to 45.7% in Q4. The company ended Q4 with $121.6 million in cash and expects cash‑flow breakeven in H2 2026 while guiding 2026 revenue to $169–174 million.Operationally, Quanterix cited $74 million of cost savings from the Akoya transaction, 94% integration completion, a CMS reimbursement rate of $897 for LucentAD Complete, and a January 2026 510(k) submission for its Alzheimer’s blood test.

#QTRX Quanterix Releases Financial Results for the Fourth Quarter and Full Year 2025

www.stocktitan.net/news/QTRX/quanterix-rele...

StockTitan

@stocktitan.net

1 month ago

Lucent Diagnostics and Life Line Screening Partner to Bring Advanced Blood-Based Diagnostics to Communities Nationwide Lucent Diagnostics (NASDAQ: QTRX) partnered with Life Line Screening to offer Lucent’s non-invasive blood-based biomarker test nationally, with programs already underway in Florida, California, and Texas. Life Line Screening will use its mobile model to provide testing at community venues and share results to help primary care physicians enable earlier intervention.Life Line Screening operates in the 48 contiguous states and hosts over 15,000 community events annually, supporting scalable access to testing for Alzheimer’s disease risk and MCI.

#QTRX Lucent Diagnostics and Life Line Screening Partner to Bring Advanced Blood-Based Diagnostics to Communities Nationwide

www.stocktitan.net/news/QTRX/lucent-diagnos...

StockTitan

@stocktitan.net

2 months ago

Quanterix Announces Landmark JAMA Study Highlighting Prognostic Value of Multi-Analyte Approach to Blood-Based Alzheimer’s Risk Profiling Quanterix (NASDAQ: QTRX) highlighted a JAMA Network Open study showing a multi‑analyte blood panel—measuring Aβ42/Aβ40, p‑Tau217, GFAP, and NfL with Simoa® technology—better predicts progression from subjective cognitive decline (SCD).The Amsterdam UMC study followed nearly 300 individuals for up to 15 years and reported an optimal multi‑analyte model C‑index of 0.90, while a single baseline multi‑marker measurement outperformed standalone p‑Tau217. Quanterix notes the same biomarkers are used in its LucentAD Complete multi‑analyte laboratory test.

#QTRX Quanterix Announces Landmark JAMA Study Highlighting Prognostic Value of Multi-Analyte Approach to Blood-Based Alzheimer’s Risk Profiling

www.stocktitan.net/news/QTRX/quanterix-anno...

StockTitan

@stocktitan.net

4 months ago

Quanterix Announces Landmark Study Demonstrating Dual GFAP/NfL Blood Test Approach for Personalized Multiple Sclerosis Monitoring Quanterix Corporation, a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced the publication of a landmark study in the high-impact journal Brain. The paper validates that multiplexed Simoa assays for Glial Fibrillary Acidic Protein and Neurofilament Light Chain establish a robust,...

#QTRX Quanterix Announces Landmark Study Demonstrating Dual GFAP/NfL Blood Test Approach for Personalized Multiple Sclerosis Monitoring

www.stocktitan.net/news/QTRX/quanterix-anno...

StockTitan

@stocktitan.net

4 months ago

Quanterix Releases Financial Results for the Third Quarter of 2025 Quanterix (NASDAQ: QTRX) reported third-quarter 2025 results for the period ending September 30, 2025, with revenue of $40.2M, up 12.3% year-over-year, and GAAP gross margin 42.8% (adjusted gross margin 45.9%).The company highlighted post‑Akoya integration progress, capturing $67M of cost synergies and projecting $85M annualized synergies and cash‑flow breakeven in 2026. Adjusted EBITDA loss was $11.9M; cash and equivalents totaled $138.1M with expected year‑end cash of ~$120M. 2025 revenue guidance reiterated at $130–$135M (pro forma $165–$170M); adjusted cash use expected $34–$38M.

#QTRX Quanterix Releases Financial Results for the Third Quarter of 2025

www.stocktitan.net/news/QTRX/quanterix-rele...

StockTitan

@stocktitan.net

7 months ago

Quanterix Accelerator Laboratory Awarded Rigorous New York State Clinical Laboratory Permit Quanterix (NASDAQ: QTRX) has achieved a significant milestone as its Accelerator Laboratory received a clinical laboratory permit from the New York State Department of Health (NYSDOH) in the Clinical Chemistry category. The lab is now CLIA-certified across all 50 states, enabling nationwide clinical testing and biomarker analysis.The state-of-the-art facility utilizes Simoa® technology for ultra-sensitive protein biomarker detection and has developed over 100 custom assays, supporting 264+ global clinical trials across neurology, immunology/oncology, and infectious diseases. The lab's Simoa® NfL Laboratory Developed Test (LDT) received approval as part of the permitting process.Additionally, the company announced the integration of Lucent Diagnostics brand under the Accelerator Laboratory, expanding its clinical and research biomarker testing capabilities.

#QTRX Quanterix Accelerator Laboratory Awarded Rigorous New York State Clinical Laboratory Permit

www.stocktitan.net/news/QTRX/quanterix-acce...

StockTitan

@stocktitan.net

7 months ago

Quanterix Strikes Deal with Activist Investor: New Board Member, Major Governance Changes Coming Cooperation agreement brings new independent director, board declassification, and majority voting reforms. See how this reshapes Quanterix's corporate governance structure.

#QTRX Quanterix Announces Cooperation Agreement with Kent Lake Capital

www.stocktitan.net/news/QTRX/quanterix-anno...

StockTitan

@stocktitan.net

8 months ago

Quanterix Completes Acquisition of Akoya Biosciences, Creating the First Integrated Platform Capable of Measuring Biomarkers Across the Blood and Tissue Continuum Quanterix (NASDAQ: QTRX) has completed its acquisition of Akoya Biosciences, creating an integrated platform for biomarker detection across blood and tissue. The transaction involved issuing 7.8 million shares of Quanterix common stock and $20 million in cash to Akoya equity holders.The merger expands Quanterix's addressable market from $1 billion to $5 billion, focusing on neurology, oncology, and immunology markets. The combined company maintains $163 million in cash post-transaction and targets profitability by 2026. As part of the deal, Scott Mendel and Dr. Myla Lai-Goldman join Quanterix's Board, replacing Martin D. Madaus and Sarah Hlavinka.

#QTRX Quanterix Completes Acquisition of Akoya Biosciences, Creating the First Integrated Platform Capable of Measuring Biomarkers Across the Blood and Tissue Continuum

www.stocktitan.net/news/QTRX/quanterix-comp...

StockTitan

@stocktitan.net

9 months ago

Quanterix Expands Reach with IVD and Large Reference Labs Quanterix Corporation (NASDAQ: QTRX) announced that its HD-X Simoa Immunoassay Analyzer received Class 1 Medical Device registration in South Korea through HS Biosystems. The company has established new global collaborations with major laboratories including ARUP Laboratories, Neurogen Biomarking, NSW Health Pathology, and Rede D'Or. The Simoa platform enables ultrasensitive biomarker detection in blood for early disease detection, particularly for Alzheimer's disease through P-tau217 testing. The technology uniquely serves multiple purposes from research discovery to clinical trials and diagnostic testing. Notable implementations include ARUP's blood test for P-tau217 using Quanterix's SP-X platform and Neurogen's at-home blood biomarker collection test, expanding accessibility to early Alzheimer's detection and treatment options.

#QTRX Quanterix Expands Reach with IVD and Large Reference Labs

www.stocktitan.net/news/QTRX/quanterix-expa...

The Insiders Fund Hedge Fund Guy

@insomniachedgefund.bsky.social

9 months ago

Insider Buying Week 06-13-25 Don't Fight the Trend The market pin action has been exceptionally strong.  Don’t fight the trend is a popular saying many people have uttered […]

investments in the current regulatory environment?
Read the full insider buying analysis: www.theinsidersfund.com/2025/06/insi...
#InsiderBuying #TheInsidersFund #QTRX #Biotech #Diagnostics #RegulatoryRisk #LifeSciences #MarketInsights #NotInvestmentAdvice

StockTitan

@stocktitan.net

9 months ago

Activist Investor With 7% Stake Accuses Quanterix Board of Silencing Shareholders to Push Through Controversial Merger Kent Lake slams Quanterix board for delaying 2025 annual meeting, claims tactics aim to push through Akoya merger without shareholder input. Get full details.

#QTRX Kent Lake Condemns Quanterix's Failure to Schedule Its 2025 Annual Meeting as a Tactic to Silence Shareholders

www.stocktitan.net/news/QTRX/kent-lake-cond...

StockTitan

@stocktitan.net

10 months ago

Kent Lake Responds to Quanterix's Post-Effective Amendment and Akoya's Superior $1.40-per-Share Alternative Proposal Kent Lake, holding 6.9% of Quanterix (QTRX) shares, responds to developments in the proposed merger with Akoya Biosciences (AKYA). The key points include: 1. Akoya received an unsolicited all-cash offer of $1.40 per share, representing a 22% premium over both Akoya's 30-day VWAP and Quanterix's implied offer. 2. Quanterix's amended merger terms, which bypass shareholder voting, include $20 million in cash and 8.4 million new shares. 3. Quanterix trades at $4.75 per share, below its net cash position, with a negative enterprise value of $80 million. Kent Lake strongly opposes any increase in Quanterix's offer, citing concerns about value destruction, balance sheet risks, and management's unrealistic break-even projections for 2026, especially given the combined companies' current $80 million burn rate.

#AKYA #QTRX Kent Lake Responds to Quanterix's Post-Effective Amendment and Akoya's Superior $1.40-per-Share Alternative Proposal

www.stocktitan.net/news/AKYA/kent-lake-resp...

StockTitan

@stocktitan.net

10 months ago

Quanterix Releases Financial Results for the First Quarter of 2025 Quanterix (QTRX) reported Q1 2025 financial results with revenue of $30.3M, down 5% YoY. The company posted a net loss of $20.5M compared to $11.2M loss in prior year. Key highlights include a new early-access program making Simoa® ONE assay kits compatible with over 20,000 flow cytometers, expanding their market reach significantly. The company is implementing $30M in annual cost reductions targeting positive cash flow by 2026. Quanterix ended Q1 with $269.5M in cash and securities. For 2025, the company expects revenues of $120-130M (5-13% YoY decline) and GAAP gross margin of 55-59%. The amended merger with Akoya Biosciences reduced equity value by 67% and increased Quanterix shareholder ownership to 84%, with closing expected in June 2025.

#QTRX Quanterix Releases Financial Results for the First Quarter of 2025

www.stocktitan.net/news/QTRX/quanterix-rele...

StockTitan

@stocktitan.net

11 months ago

Quanterix Slashes Share Issuance in Amended Akoya Merger Deal: Key Changes Revealed Quanterix reduces share issuance by 9M+ in revised Akoya merger. New terms include $20M cash + 7.76M shares. Strong shareholder backing secured. See full details.

#QTRX #AKYA Quanterix and Akoya Biosciences Announce Amended Merger Agreement

www.stocktitan.net/news/QTRX/quanterix-and-...

StockTitan

@stocktitan.net

11 months ago

Quanterix Under Fire: Top Investor Warns of 'Value Destructive' $30M Deal with Struggling Akoya Kent Lake condemns Quanterix's $30M convertible notes deal with Akoya as risky 'backdoor financing.' Urges shareholders to reject merger proposals. Full analysis inside.

#QTRX #AKYA Kent Lake Comments on Quanterix’s Value Destructive Bridge Financing for Financially Troubled Akoya

www.stocktitan.net/news/QTRX/kent-lake-comm...

Market Wire News

@marketwirenews.com

1 year ago

BREAKING NEWS: ( NASDAQ: #QTRX ) Quanterix Showcases Innovation Powered by Simoa at AD/PD with Customer Research and New Dried Blood Spot Extraction Kit

StockTitan

@stocktitan.net

1 year ago

Quanterix Showcases Innovation Powered by Simoa® at AD/PD with Customer Research and New Dried Blood Spot Extraction Kit Quanterix (NASDAQ: QTRX) has unveiled a new dried blood spot (DBS) extraction kit for their Simoa® assay platform at the AD/PD conference in Vienna. The innovative kit aims to revolutionize neurodegenerative disease testing by enabling biomarker measurement from dried blood spots, offering a more cost-effective and less invasive alternative to traditional venous blood draws.The DBS extraction kit, developed in collaboration with the DROP-AD Project at the University of Gothenburg, includes buffers and sample preparation protocols. Validation studies demonstrated correlation rates of 0.75 to 0.86 between DBS samples and venous samples in simulated CSF testing using Simoa ALZpath p-Tau 217.The company's Simoa® technology is being featured in over 80 posters and presentations at the conference, highlighting its impact on neurodegenerative disease research. This advancement aims to improve accessibility to biomarker testing, particularly in remote or resource- settings, and expand participation in Alzheimer's research among under-represented populations.

#QTRX Quanterix Showcases Innovation Powered by Simoa® at AD/PD with Customer Research and New Dried Blood Spot Extraction Kit

www.stocktitan.net/news/QTRX/quanterix-show...

Anu Bansal

@stockholderrights.bsky.social

1 year ago

Kent Lake Partners nominated Board candidates to Quanterix #QTRX

#microcap #stockholderdemocracy #activistinvestor

Disclaimer

linktr.ee/disclaimer462

StockTitan

@stocktitan.net

1 year ago

Quanterix Releases Financial Results for the Fourth Quarter of 2024 Quanterix (NASDAQ: QTRX) reported Q4 2024 financial results, marking its seventh consecutive quarter of double-digit revenue growth. Q4 revenue reached $35.2 million, up 11% year-over-year, with a GAAP gross margin of 63.0%. The company posted a net loss of $11.6 million.Full-year 2024 revenue was $137.4 million, a 12% increase from 2022, with a net loss of $38.5 million. The company ended 2024 with $291.7 million in cash and equivalents.Key developments include:Announced acquisition of Akoya Biosciences in an all-stock transaction, expected to close in Q2 2025Plans to launch Simoa ONE instrument by end of 2025Acquired EMISSION for bead manufacturing capabilitiesReceived FDA Breakthrough Designation for LucentAD Complete testFor 2025, Quanterix projects standalone revenue of $140.0-146.0 million (2-6% growth) with gross margin of 59-63%.

#QTRX Quanterix Releases Financial Results for the Fourth Quarter of 2024

www.stocktitan.net/news/QTRX/quanterix-rele...

StockTitan

@stocktitan.net

1 year ago

Quanterix Merger Under Fire: Top Investor Reveals Shocking 82% Value Disparity Kent Lake challenges Quanterix-Akoya merger, citing unfair valuation split, governance concerns, and NIH funding risks. Key investor demands answers on controversial deal structure.

#QTRX #AKYA Kent Lake Urges Quanterix Management to Address Key Questions Regarding its Proposed Transaction with Akoya Biosciences During Today’s Earnings Call

www.stocktitan.net/news/QTRX/kent-lake-urge...

StockTitan

@stocktitan.net

1 year ago

Quanterix Merger Under Fire: 7.25% Stakeholder Reveals Shocking Valuation Concerns Kent Lake challenges Quanterix-Akoya merger, citing 40% stock decline and questionable $30M financing. Key investor presents alternative growth strategy focusing on Alzheimer's testing.

#QTRX #AKYA Kent Lake Issues Investor Presentation Detailing Opposition to Quanterix’s Proposed Merger with Akoya Biosciences

www.stocktitan.net/news/QTRX/kent-lake-issu...

StockTitan

@stocktitan.net

1 year ago

Can Quanterix's Akoya Acquisition Transform Biomarker Detection and Deliver $1B Revenue? Quanterix projects $40M in annual synergies and 15% EBIT margins through Akoya acquisition, creating the first integrated blood-tissue biomarker detection platform.

#QTRX Quanterix Highlights Compelling Benefits of Akoya Biosciences Acquisition

www.stocktitan.net/news/QTRX/quanterix-high...

StockTitan

@stocktitan.net

1 year ago

Quanterix Merger Battle: 5.9% Stakeholder Reveals Why $42M Deal Could Destroy Shareholder Value Kent Lake Capital slams proposed Akoya merger, highlighting Quanterix's superior revenue and Alzheimer's potential. Calls for alternatives including $1B+ sale exploration.

#QTRX #AKYA Kent Lake Issues Letter to Quanterix Shareholders Regarding Opposition to the Company’s Proposed Merger with Akoya Biosciences

www.stocktitan.net/news/QTRX/kent-lake-issu...

Thiard News@F4F

@newsen.bsky.social

1 year ago

Pomerantz Law Firm Launches Investigation into Quanterix Corp. for Investor Claims of Securities Fraud Pomerantz LLP has initiated an investigation into potential securities fraud involving Quanterix Corporation. The firm's probe arises after significant financial discrepancies were discovered within the company.

Pomerantz Law Firm Launches Investigation into Quanterix Corp. for Investor Claims of Securities Fraud #United_States #New_York #QTRX #Pomerantz_LLP #Quanterix_Corp

Thiard News@F4F

@newsen.bsky.social

1 year ago

Kuehn Law Urges Investors of LGTY, QTRX, RDW, and AZPN to Reach Out Kuehn Law is investigating potential claims concerning mergers involving LGTY, QTRX, RDW, and AZPN. Shareholders are encouraged to participate.

Kuehn Law Urges Investors of LGTY, QTRX, RDW, and AZPN to Reach Out #United_States #New_York #QTRX #Kuehn_Law #LGTY

Thiard News@F4F

@newsen.bsky.social

1 year ago

Rosen Law Firm Launches Investigation into Quanterix Corporation's Securities Practices Amid Allegations Rosen Law Firm investigates potential securities claims for Quanterix Corporation shareholders, alleging misleading business information. Join the class action.

Rosen Law Firm Launches Investigation into Quanterix Corporation's Securities Practices Amid Allegations #United_States #New_York #Quanterix_Corporation #QTRX #Rosen_Law_Firm

StockTitan

@stocktitan.net

1 year ago

Quanterix Achieves 12% Revenue Growth in 2024, Marks Seventh Quarter of Double-Digit Growth Quanterix reports $137.2M in 2024 revenue with strong Accelerator segment growth of 36% YoY, maintains momentum despite challenging market conditions. Cash position remains solid at $292M.

#QTRX Quanterix Provides Update on Financial Performance

www.stocktitan.net/news/QTRX/quanterix-prov...

Market Wire News

@marketwirenews.com

1 year ago

BREAKING NEWS: ( NASDAQ: #QTRX ) SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates ACCD, ESSA, AKYA, QTRX on Behalf of Shareholders

StockTitan

@stocktitan.net

1 year ago

Quanterix to Acquire Akoya in Groundbreaking Biomarker Platform Merger, $40M Synergies Expected Quanterix merges with Akoya Biosciences in all-stock deal, creating first integrated blood and tissue biomarker platform. Combined $220M revenue and $175M cash position strengthen market presence.

#QTRX #AKYA Quanterix to Acquire Akoya Biosciences, Creating the First Integrated Solution for Ultra-Sensitive Detection of Blood- and Tissue-Based Protein Biomarkers

www.stocktitan.net/news/QTRX/quanterix-to-a...